ERBB2 and gastroesophageal junction adenocarcinoma: The trial was designed as an open labeled, randomized multicenter phase III study in HER2-positive patients with histologically confirmed inoperable locally advanced, recurrent, or metastatic gastroesophageal junction adenocarcinoma (46).